Lee et al. [52] showed that the combination of a histone deacetylase type I inhibitor, entinostat, with lapatinib synergistically inhibited proliferation in HER2+ breast cancer cells, including IBC SUM190 cells. The gene discussed is ERBB2; the disease is breast carcinoma.